TB-500 for Tendinopathy: Protocol, Dosing, and What to Expect

What this protocol is for

Tendinopathy is one of TB-500 strongest cases. Tendon tissue is poorly vascularised, slow to heal, and notoriously stubborn under conventional rehab. The TB-500 mechanism (actin binding, cell migration, angiogenesis, stem-cell mobilisation) addresses the rate-limiting steps directly. The peptide brings vascular support to a tissue that has very little of it, mobilises the cells responsible for collagen reorganisation, and gives the tendon a real path forward when physio alone has plateaued.

The clinical pattern is consistent across user reports: the Achilles that has been bothering you for six months. The chronic tennis or golfer's elbow that refuses to resolve. The patellar tendon that flares every time training picks up. The rotator cuff insertion that has not moved despite a full physio block. Anecdotally, users running TB-500 for tendinopathy report meaningful change in weeks 4 to 8, not the first fortnight. The mechanism is back-loaded; the cycle delivers most of its value in the second half.

Used by many in the recovery / biohacking space stacked with BPC-157, where the combined protocol is the default for non-trivial tendon cases. Research shows the thymosin beta-4 mechanism is well characterised; the case for clinical tendinopathy specifically is built more on animal models, anecdotal human reports, and mechanistic plausibility than on phase-3 trials. Run this as a tactical, legal performance layer on top of the loading and rehab work that tendons actually need.

Dose for tendinopathy

2 to 2.5 mg subcutaneous twice weekly, with a 4-week loading phase at 5 mg per week for chronic tendon cases. Local-site injection is occasionally used near accessible tendons (Achilles, patellar) but the long half-life means systemic abdominal subcutaneous is just as effective for most cases. Loading is non-optional for tendinopathy; chronic tendon tissue needs the front-loaded push.

Cycle length

8 weeks total: 4 weeks loading at 5 mg/week, 4 weeks maintenance at 2 to 2.5 mg/week. Chronic tendinopathy cases sometimes need a second 8-week cycle after a 2 to 4 week washout. Cycling shorter than 8 weeks consistently under-delivers on tendon work.

Stack pairings

Commonly stacked with BPC-157.

Expected timeline

Week 1–3: systemic exposure builds, minimal subjective change. Week 4–6: pain on movement begins to drop, tendon tolerance for loading improves. Week 6–8: structural plateau on the tendon itself, eccentric loading progression starts feeling realistic. The bigger functional gains land weeks 5 to 8. Chronic cases (12+ months) may need a second cycle to see full remodeling.

Common mistakes

• Running TB-500 alone for tendinopathy. The stack with BPC-157 is the default; alone, TB-500 underdelivers on the local soft-tissue work.
• Skipping the loading phase. Chronic tendon tissue needs the front-loaded systemic push. Starting at 2 mg/week wastes the first 3 to 4 weeks of the cycle.
• Stopping eccentric loading work during the cycle. The peptide supports remodeling; eccentric load drives the direction of the remodeling. Without both, the tendon heals but does not heal into the correct architecture.
• Cycling shorter than 8 weeks. Tendon work is the back half of the cycle. Stopping at week 4 means stopping before the meaningful structural gains.
• Expecting dramatic week-one change. TB-500 for tendinopathy is back-loaded. Patience through weeks 1 to 3 is part of the protocol.